The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year




Total Raised


Date of IPO


Market Cap


Stock Price


About Sera Prognostics

Sera Prognostics (NASDAQ:SERA) develops diagnostic tests for the early prediction of a woman's individualized risk prediction of preterm birth and other pregnancy complications. Sera's tests are designed to help better inform the care of a mother and her unborn child during pregnancy, and potentially lead to improved health. The Company has fully enrolled the Proteomic Assessment of Preterm Risk (PAPR) clinical study, to validate the performance of its PreTRM Test for predicting the risk of preterm birth in the United States.

Sera Prognostics Headquarter Location

2749 East Parleys Way Suite 200

Salt Lake City, Utah, 84109,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Sera Prognostics

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Sera Prognostics in 2 CB Insights research briefs, most recently on May 12, 2021.

Expert Collections containing Sera Prognostics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Sera Prognostics is included in 6 Expert Collections, including Women's Health & Wellness.


Women's Health & Wellness

1,456 items

Startups focused on providing products and services catering to women's health and wellbeing.


Medical Devices

8,285 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Health Monitoring & Diagnostics

2,394 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance



1,750 items



1,265 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data


Health IT

7,900 items

Sera Prognostics Patents

Sera Prognostics has filed 21 patents.

The 3 most popular patent topics include:

  • Women's health
  • Obstetrics
  • Infancy
patents chart

Application Date

Grant Date


Related Topics




Obstetrics, Midwifery, Progestogens, Women's health, Neonatology


Application Date


Grant Date



Related Topics

Obstetrics, Midwifery, Progestogens, Women's health, Neonatology



Latest Sera Prognostics News

Sera Prognostics’ Data Shows Benefit of Preterm Birth Risk Assessment Tool

May 24, 2022

Sera Prognostics , a company focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients to address preterm birth risks, presented data demonstrating the health and economic benefit of its PreTRM test-and-treat strategy. The study, using patient data from the Multicenter Assessment of Spontaneous Preterm Birth Risk Predictor Study, modeled the effects of two test-and-treat intervention strategies (case management alone and a multi-modal strategy of case management together with progesterone treatment) in subjects determined to be at higher risk of spontaneous preterm birth by their measured PreTRM Test results. The analysis demonstrated that with case management alone: Neonatal and maternal length of hospital stay was reduced significantly by 22% and 8.5%, respectively. Moderate-to-severe neonatal morbidity and mortality fell significantly by 29%. Neonatal costs associated with hospital stay decreased by 16% after intervention cost but did not reach significance. Adding pharmacological treatment in the multi-modal strategy strengthened reductions and significance. “Consistent with previously published data, this study, conducted by leading researchers in maternal-fetal medicine and neonatology, continues to demonstrate significant benefits of Sera’s test-and-treat strategy in reducing adverse impacts of prematurity,” says Gregory C. Critchfield, MD, MS, Chairman and Chief Executive Officer of Sera Prognostics. “This work highlights the benefit of biomarker testing to enable more proactive interventions in pregnancies that are truly at higher risk for preterm delivery, yielding cost-savings as a consequence of improving newborn health.” The PreTRM test is a broadly clinically validated commercially available blood test that provides an early individual risk assessment for spontaneous preterm birth in asymptomatic, singleton pregnancies. Sera Prognostics is a health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care. The company aims to deliver early, pivotal information in pregnancy to physicians, enabling them to improve the health of their patients, resulting in reductions in the costs of healthcare delivery. Share:

Sera Prognostics Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Sera Prognostics Rank

  • When was Sera Prognostics founded?

    Sera Prognostics was founded in 2008.

  • Where is Sera Prognostics's headquarters?

    Sera Prognostics's headquarters is located at 2749 East Parleys Way, Salt Lake City.

  • What is Sera Prognostics's latest funding round?

    Sera Prognostics's latest funding round is IPO.

  • How much did Sera Prognostics raise?

    Sera Prognostics raised a total of $267.57M.

  • Who are the investors of Sera Prognostics?

    Investors of Sera Prognostics include Catalyst Health Ventures, Domain Associates, Blue Ox Capital, Anthem, Parian Global Management and 14 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.